Skip to main content
OpenTrials
Completed

NCT Number: NCT02266537

Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers

The study was aimed to evaluate the pharmacological effect of different α-antagonists on phenylephrine induced pupil size in healthy male volunteers as pharmacological basis for Intraoperative floppy iris syndrome (IFIS)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

21 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male
  • Age ≥ 21 and ≤ 55 years
  • Body Mass Index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2
  • Signed and dated written informed consent in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

  • Any finding of the medical examination (including blood pressure, pulse rate and Electrocardiogram (ECG)) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (> 24:00 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study or during the study
  • Use of any drugs which might influence the results of the trial up to seven days prior to enrolment in the study or during the study
  • Participation in another trial with an investigational drug (≤ two months prior to administration or during the trial)
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking on in-house trial days
  • Alcohol abuse (> 60 g/day)
  • Drug abuse
  • Blood donation (≥ 100 mL within four weeks prior to administration or during the trial)
  • Any laboratory value outside the clinically accepted reference range
  • Excessive physical activities within the last week before the trial or during the trial

The following exclusion criteria are of special interest for this study:

  • Hypersensitivity to any alpha agonist, or to phenylephrine
  • Supine blood pressure at screening of systolic < 110 mmHg and diastolic < 60 mmHg
  • Ophthalmological criteria:
  • Corrected visual acuity < 0.5
  • Refractive Error with a spherical equivalent > +6 or smaller - 6 D
  • Elevated intraocular pressure (higher than 22 mmHg)
  • Relevant anisocoria or pupil deformation
  • History of eye surgery apart from laser trabeculoplasty less than three months previously or extraocular surgery such as strabismus surgery
  • Topical ocular medication influencing IOP (intraocular pressure) or pupil size within 3 months prior to study-start

Treatment and study plan

Tamsulosin

Drug

Other names: Alna®

Alfuzosin

Drug

Other names: Uroxatral® uno

Doxazosin

Drug

Other names: Cardular PP Uro®

Placebo

Drug

Primary outcomes

  1. Sum of changes from baseline in the mean pupil diameters

    Time frame: Baseline, 60 and 80 min after administration of phenylephrine (PE)

Secondary outcomes

  1. Change from baseline in mean diameter of both pupils

    Time frame: Baseline, 60 and 80 min after administration of phenylephrine (PE)

  2. Change from baseline in mean diameter of both pupils

    Time frame: one week after cessation of drug

  3. Concentration of the analyte in plasma

    Time frame: Up to 29 days after first administration of α-antagonists

  4. Number of participants with clinically significant changes in vital signs

    Time frame: Up to 8 days after last pupillometry

  5. Number of participants with abnormal changes in clinical laboratory parameters

    Time frame: Up to 8 days after last pupillometry

  6. Number of participants with Adverse Events

    Time frame: Up to 8 days after last pupillometry

  7. Assessement of global tolerability by investigator on a 4 point scale

    Time frame: 8 days after last pupillometry

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A Parallel Group Study With Three Different α-antagonists and Placebo Once Daily Over Three Weeks to Assess Their Influence on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers

Important dates

Study start
2005
Primary completion
2006
First posted
Oct 17, 2014
Registry last updated
Oct 17, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.